- |||||||||| paracetamol / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients (clinicaltrials.gov) - Mar 30, 2017 P=N/A, N=0, Withdrawn, Active, not recruiting --> Completed N=40 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2017 --> Mar 2015
- |||||||||| Pegasys (pegylated interferon α -2a) / Roche, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial completion, Enrollment change, Trial primary completion date: DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) (clinicaltrials.gov) - Mar 29, 2017 P4, N=14, Completed, Trial primary completion date: Jun 2016 --> Jun 2018 Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Jun 2015 --> Nov 2015
- |||||||||| Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Trial completion: Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths (clinicaltrials.gov) - Mar 28, 2017 P2, N=123, Completed, Active, not recruiting --> Completed | Trial primary completion date: Aug 2018 --> Sep 2016 Active, not recruiting --> Completed
- |||||||||| sorafenib / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Metastases: Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 27, 2017 P3, N=35, Terminated, Trial primary completion date: Jul 2016 --> Dec 2016 N=320 --> 35 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Mar 2017; lack of enrolment
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: High Fructose Corn Syrup (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=47, Completed, Active, not recruiting --> Terminated Active, not recruiting --> Completed | N=30 --> 47 | Trial primary completion date: Feb 2017 --> Mar 2016
- |||||||||| Phase classification, Trial primary completion date, Surgery, Metastases: Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=30, Active, not recruiting, Recruiting --> Active, not recruiting Phase classification: P1 --> P=N/A | Trial primary completion date: Apr 2016 --> Apr 2018
- |||||||||| avadomide (CC-122) / BMS
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer (clinicaltrials.gov) - Mar 20, 2017 P1b, N=12, Terminated, N=40 --> 12 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Dec 2016; Slow enrollment and business decision. No safety concerns were identified for the study drugs.
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, Victrelis (boceprevir) / Roche, Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date, HEOR: Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir (clinicaltrials.gov) - Mar 15, 2017 P=N/A, N=50, Completed, No safety concerns were identified for the study drugs. Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Sep 2014 --> Apr 2013
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: AEMD-IDE-20: Safety Study of the Aethlon Hemopurifier (clinicaltrials.gov) - Mar 14, 2017
P=N/A, N=8, Terminated, Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Sep 2014 --> Apr 2013 N=10 --> 8 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Mar 2017; Adequate safety data has been accumulated and the # of patients meeting inclusion criteria has diminished.
- |||||||||| DC Bead (E7040) / Eisai, Boston Scientific
Trial completion, Trial primary completion date: DEBDOX: Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 13, 2017 P2, N=24, Completed, N=10 --> 8 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Mar 2017; Adequate safety data has been accumulated and the # of patients meeting inclusion criteria has diminished. Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Aug 2015
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Mar 10, 2017 P2, N=299, Active, not recruiting, Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Aug 2015 Trial primary completion date: Jun 2016 --> Sep 2017
- |||||||||| Inlyta (axitinib) / Pfizer
Trial completion, Trial primary completion date, Metastases: Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 11, 2017 P2, N=45, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Mar 2016
|